We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -1.37% | 18.00 | 17.50 | 18.50 | 18.50 | 18.00 | 18.25 | 336,970 | 12:53:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.34 | 16.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/4/2017 16:11 | crikey .. 60's looming again ? surely not There is no getting away that the share price has been a huge disappointment over the last year or so despite v good newsflow. Each event that has supposed to catapult us to £1 has come and gone. and we sit within the irritating range of the last 15 months Ho hum ... let's hope the next event does the trick :O/ | onedayrodders | |
19/4/2017 16:10 | Scotty..Lol.. | talkingtrade | |
19/4/2017 16:09 | You can get tablets for it tt,you should look fine again tomorrow :) | scotty1 | |
19/4/2017 16:08 | Looking at IMM's trades today I highly doubt people are leaving OPTI for IMM lol | f3rdinand | |
19/4/2017 16:07 | Not looking so good today. | talkingtrade | |
19/4/2017 16:05 | I think people are moving into ImmuPharma (IMM). Share price 57p Market Cap £75m 1) ‘Lupuzor’ 2) All patients now recruited. 3) Results expected Q1 2018. 4) Incremental announcements expected throughout 2017. 5) On FDA’s “fast track” “special protocol” route after strong safety and efficacy in Phase 2, so if IMM adheres to same protocol as Phase 2b and delivers positive results, FDA will approve and not request further trial with different endpoints or outcomes. 6) Potential “multi-billion dollar sales”. 7) Currently 100% owned by IMM. 8) Very little competition, with only one other Lupus drug approved in last 50 years - GSK’s Benlysta reached sales over $400m in 2015, with annual sales predicted at $1bn by 2020. 9) IMM’s Lupuzor already demonstrated in Phase IIb to be safer and more effective than Benlysta, and is expected to have lower pricing. 10) Fully cashed up from £4.1m fund raise in March 2017, enabling it to complete pivotal Phase 3 trials and progress other pipeline projects. Northland Capital has 171p current valuation on IMM. With the blockbuster sales potential, little competition, good Phase 2 and FDA fast track and special protocol status, I personally think it could be £7 to £10 if the Phase 3 results are good in Q1 2018. www.immupharma.org/s www.youtube.com/watc | top tips | |
19/4/2017 15:59 | Some funny mm games being played today. You can still buy at 72p! I think all those recent 72p trades are buys. Trying to make buys look like sells deliberately? | parob | |
19/4/2017 15:50 | well, i've grabbed a few at 72.1p, and very pleased.. sorry elrico. | belgrano2 | |
19/4/2017 15:42 | Oddly you can sell for 72.1 and buy for 72p! | parob | |
19/4/2017 15:38 | Sorry peeps....I have done a Parsnip and put an order in for 111,111 shares at 71. MM walking it down for me. If they find out I ain't got the money... :) | elrico | |
19/4/2017 15:37 | I'm sure the sell price will be well above my top up price in the next few weeks! Thanks for the concern though! :) | f3rdinand | |
19/4/2017 15:34 | Keep topping up and losing even more money, what a great strategy you guys have! | branboyd1 | |
19/4/2017 15:33 | If you look at the trades there have actually been more buys (shown) than sells today! There is clearly someone dumping a lot of shares in the background! The only logical answer would be YSF again...when they've finished their batch we'll be off north again IMO! | f3rdinand | |
19/4/2017 15:30 | It is fair to say no one predicted this fall. In fact I, along with others, thought we might see a climb back to over 80p in the run up to results. Still could happen of course but It will be interesting to hear people's views on this fall. | rafboy | |
19/4/2017 15:25 | Today is a prime example of why increased share price predictions make mockery of these foolish posters 99% of the time | judijudi | |
19/4/2017 15:18 | That's because they have not forecast this drop. It's as if the mm's have suddenly decided to catch/stop people out and possibly try and get shares on their books, he says optimistically, there are of course always willing shareholders to top up. Surely there is nothing more to it. | lukead | |
19/4/2017 15:15 | judi, im waiting for an explanation from marnewton.. marnewton 12 Apr '17 - 20:04 - 22178 of 22178 Things are looking quite good for a rise from here. I think the higher low is in. The last two dojis have found support on the 50% retracement and both have closed above the rising (so also support) 50 day SMA (blue line). And the 200 day SMA (red) is flat-lining. It won't take much to turn it up. | currypasty | |
19/4/2017 15:11 | Didn't see any chartist predict this!! | judijudi | |
19/4/2017 15:09 | 71/72 is not a pretty sight. | lukead | |
19/4/2017 15:07 | I'm wondering if YSF are clearing out another batch before product launch? MM's trying to create some interest!? | f3rdinand | |
19/4/2017 15:05 | Just picked up another 14500- missed the 71p bargain by a matter of milliseconds | f3rdinand | |
19/4/2017 15:04 | Not worried at all. Just took another 5k. What an opportunity when so close to product launches! | parob | |
19/4/2017 15:02 | Just been out with the dog, what has happened here. We weren't out that long!! | rafboy | |
19/4/2017 15:02 | Surely buye must come in around this level?i know i just had another little top up,cannot see there being any bad news,seems to be all mostly small pi sells. | scotty1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions